Acute Phosphate Nephropathy?An Emerging Issue

Sica, Domenic A.; Carl, Dan; Zfass, Alvin M.

doi:10.1111/j.1572-0241.2007.01047.x

Cited by 34 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Un estudio encontró niveles de fósforo, entre los pacientes con función renal normal, que oscilaron entre 3,7 a 7,3 mg/dL, después de la administración de fosfato de sodio 7 . Otro estudio encontró niveles de fósforo superiores a 8 mg/dl en 28% de los pacientes tratados con fosfato de sodio 8 .…”

Section: Ce Dfunclassified

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Pineda¹,

Molano²,

Flórez³

et al. 2016

acnef

View full text Add to dashboard Cite

Rev. Colomb. Nefrol. 2016; 3(1): 52 -57 Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado. Reporte de un caso 52Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado.Reporte de un casoRoberto Pineda 1 , Alejandra Molano 2 , Adriana Flórez 3 , Roberto D`Achiardi 2 , Benjamín Wancjer 2 ResumenLa nefropatía por fosfato de sodio es una forma de lesión renal que ocurre posterior al uso de laxantes que contienen fosfato de sodio. Puede presentarse de manera aguda o crónica según el tiempo de utilización de dichos medicamentos utilizados para la preparación colónica. La forma aguda puede resolverse con un adecuado tratamiento, pero la forma crónica puede causar daño renal irreversible. Este caso se trata de una paciente con trasplante renal, en seguimiento en la Fundación Cardioinfantil en Bogotá, Colombia, en quien se utilizó fosfato de sodio para una preparación de colonoscopia y se presentó a nuestro servicio con una lesión renal aguda.Palabras clave: Enfermedad renal crónica, nefropatía por fosfato de sodio, diagnóstico (fuente DeCS). Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report AbstractSodium phosphate nephropathy is a form of renal injury that occurs following the use of laxatives containing sodium phosphate, which can present acutely or chronically after the administration of these drugs used in colonic preparation for colonoscopy. The acute form can resolve with adequate treatment, but the chronic form may cause irreversible kidney damage. The case we report is about a kidney transplantantion patient in whom sodium phosphate was used for colonoscopy preparation debuting with acute kidney injury.

show abstract

Section: Ce Dfunclassified

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Pineda¹,

Molano²,

Flórez³

et al. 2016

acnef

View full text Add to dashboard Cite

show abstract

“…Additionally, a recent series of reports [7][8][9] described acute phosphate nephropathy followed by chronic renal insufficiency after taking NaP for bowel preparation. Nephrocalcinosis is the cause of renal injury and occurs when the concentration of phosphate increases, and calcium phosphate crystals are deposited in the renal tubules [9] .…”

Section: Times For the Completion Of The Bowel Preparationmentioning

confidence: 99%

“…Although this agent provides superior cleansing and is well-tolerated by most patients, there are concerns about its safety that are related to its osmotic action [5,6] . Moreover, recent reports [7][8][9] of renal injury associated with this agent have raised additional concerns. Given the mechanistic causes of the occurrence of adverse events, the use of reduced doses of NaP might decrease these potential risks.…”

Section: Introductionmentioning

confidence: 99%

Bowel preparation for colonoscopy using standardvsreduced doses of sodium phosphate: A single-blind randomized controlled study

Koshitani¹

2014

WJGE

View full text Add to dashboard Cite

show abstract

“…7,8,12 Patient co-morbidity, particularly congestive cardiac failure (CCF), advanced liver disease and renal failure, has been suggested to be an additional independent risk factor. 13,14 However, there have been no reports of renal dysfunction or electrolyte imbalance with PEGbased oral bowel cleansing agents. 13 The recently published Consensus guidelines for the prescription and administration of oral bowel cleansing agents (jointly developed by the Royal College of Surgeons, British Society of Gastroenterology, British Society of Gastrointestinal and Abdominal Radiology, Renal Association and the Royal College of Radiologists) recommends an eight-step process for all patients when prescribing oral bowel cleansing agents.…”

Section: Introductionmentioning

confidence: 99%

Service implications of implementing guidance for oral bowel cleansing agents in colonoscopy

Pk¹,

Ms²,

Sm³

et al. 2011

J R Coll Physicians Edinb

View full text Add to dashboard Cite

Introduction:Bowel preparation has led to serious adverse events. Consequently, regulatory and advisory bodies have issued guidance, including a risk stratification of patients, aiming to minimise this risk. Aims: To determine the impact of the new guidance on our current practice of Picolax used in colonoscopy with regard to patient stratification, compliance and service implementation. Methods: Patients listed for day case colonoscopy during October 2009 were audited using data from the hospital and endoscopy databases. A follow-up, structured patient telephone interview evaluated side effects, the assessment process and patient experience. Results: Of the participating 112 patients, 97.4% were clinically reviewed before colonoscopy, 98.3% received written instructions and 70% verbal instructions. None had their preparation dispensed by a regulated professional. Although 62% of patients were retrospectively identified as 'at risk' (elderly, with congestive cardiac failure, cirrhosis or chronic kidney disease or on angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics or non-steroidal anti-inflammatory drugs), none were identified before their procedure. Significant events (postural hypotension, collapse, dizziness, palpitations, faint) were seen in 4.4%, all of whom could potentially be identified as 'at risk' using a stratification of low estimated glomerular filtration rate with relevant co-morbidity (congestive cardiac failure or cirrhosis). Conclusions: Given the difficulties with compliance and the high prevalence of 'at risk' patients, the implementation will be challenging and require significant service redesign.

show abstract

Acute Phosphate Nephropathy?An Emerging Issue

Cited by 34 publications

References 15 publications

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

Bowel preparation for colonoscopy using standardvsreduced doses of sodium phosphate: A single-blind randomized controlled study

Service implications of implementing guidance for oral bowel cleansing agents in colonoscopy

Contact Info

Product

Resources

About